Real-life efficacy and safety of idelalisib in 55 double-refractory follicular lymphoma patients. Isidori A, Loscocco F, Visani G, Paolasini S, et al. Br J Haematol 2022 Aug 24. doi: 10.1111/bjh.18426.

Read + Share

Amedeo Smart

Independent Medical Education

Isidori A, Loscocco F, Visani G, Paolasini S, et al. Real-life efficacy and safety of idelalisib in 55 double-refractory follicular lymphoma patients. Br J Haematol 2022 Aug 24. doi: 10.1111/bjh.18426.
PMID: 36002151